Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its target price lowered by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday, The Fly reports. A number of other equities research analysts have also issued reports on CHRS. StockNews.com started coverage on Coherus BioSciences in a research note on Thursday, May […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price objective trimmed by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday morning, The Fly reports. CHRS has been the subject of a number of other research reports. HC Wainwright decreased their price objective on shares of Coherus BioSciences from $26.00 […]
Explore how AI is revolutionizing healthcare, from improved diagnosis and treatment to drug discovery and development, with Microsoft s privacy-focused version